Dendritic cells in IBD pathogenesis: An area of therapeutic opportunity?

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 112-120

  Bates, Jennifer ^a   Diehl, Lauri ^a  

^a GENENTECH INC   (United States)

Author keywords

colitis; Crohn's disease; dendritic cell; inflammation; inflammatory bowel disease; mucosal immunity

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; DECTIN 1; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PATTERN RECOGNITION RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

AUTOPHAGY; CELLULAR IMMUNITY; COLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; ENTERITIS; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETICS; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; ULCERATIVE COLITIS;

COLITIS; CROHN'S DISEASE; DENDRITIC CELL; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MUCOSAL IMMUNITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; DENDRITIC CELLS; DRUG DISCOVERY; GASTROINTESTINAL AGENTS; HUMANS; IMMUNITY, MUCOSAL; INTESTINES; MICE; MOLECULAR TARGETED THERAPY;

EID: 84890288893     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4277     Document Type: Review

References (135)

1. Abraham C, Cho JH,. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078.
2. Levine A, Griffiths A, Markowitz J, et al., Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-1321.
3. Kaser A, Zeissig S, Blumberg RS,. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573-621.
4. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
5. Danese S, Fiocchi C,. Ulcerative colitis. N Engl J Med 2011; 365: 1713-1725.
6. Farmer RG, Hawk WA, Turnbull RB,. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 68: 627-635.
7. Gramlich T, Petras RE,. Pathology of inflammatory bowel disease. Semin Pediatr Surg 2007; 16: 154-163.
8. Keighley MRB, Eastwood D, Ambrose NS,. Incidence and microbiology of abdominal and pelvic abscess in Crohn's disease. Gastroenterology 1982; 83: 1271-1275.
9. Maeda K, Okada M, Yao T, et al., Intestinal and extraintestinal complications of Crohn's disease: predictors and cumulative probability of complications. J Gastroenterol 1994; 29: 577-582.
10. Jenkins D, Balsitis M, Gallivan S, et al., Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997; 50: 93-105.
11. Scholmerich J, Warren B,. Differential diagnosis and other forms of inflammatory bowel disease. In Inflammatory Bowel Diseases, Satsangi J, Sutherland LR, (eds). Churchill Livingstone: London, 2003. pp. 199-215.
12. Guindi M, Riddell RH,. Indeterminante colitis. J Clin Pathol 2004; 57: 1233-1244.
13. Tremaine WJ,. Diagnosis and treatment of indeterminate colitis. Gastroenterol Hepatol 2011; 7: 826-828.
14. Loftus CG, Loftus EVJ, Harmsen SW, et al., Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13: 254-261.
15. Herrinton LJ, Liu L, Lafata JE, et al., Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis 2007; 13: 451-461.
16. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al., The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-1429.
17. Lambrecht BN, Hammad H,. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet 2010; 376: 835-843.
18. Hugot J-P, Chamaillard M, Zouali H, et al., Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
19. Ogura Y, Bonen DK, Inohara N, et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
20. Jostins L, Ripke S, Weersma RK, et al., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.
21. Zhernakova A, van Diemen CC, Wijmenga C,. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nature Rev Genet 2009; 10: 43-55.
22. Budarf ML, Labbé C, David G, et al., GWA studies: rewriting the story of IBD. Trends Genet 2009; 25: 137-146.
23. Inohara N, Chamaillard M, McDonald C, et al., NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005; 74: 355-383.
24. Strober W, Watanabe T,. NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease. Mucosal Immunol 2011; 4: 484-495.
25. Cho JH,. The genetics and immunopathogenesis of inflammatory bowel disease. Nature Rev Immunol 2008; 8: 458-466.
26. Lesage S, Zouali H, Cézard J-P, et al., CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845-857.
27. Abraham C, Cho JH,. Functional consequences of NOD2 (CARD15) mutations. Inflamm Bowel Dis 2006; 12: 641-650.
28. Girardin SE, Travassos LH, Hervé M, et al., Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem 2003; 278: 41702-41708.
29. Inohara N, Ogura Y, Fontalba A, et al., Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003; 278: 5509-5512.
30. Watanabe T, Asano N, Murray PJ, et al., Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008; 118: 545-559.
31. Hedl M, Li J, Cho JH, et al., Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci U S A 2007; 104: 19440-19445.
32. Strober W, Murray PJ, Kitani A, Watanabe T,. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006; 6: 9-20.
33. Cooney R, Baker J, Brain O, et al., NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nature Med 2010; 16: 90-97.
34. Travassos LH, Carneiro LAM, Ramjeet M, et al., Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nature Immunol 2010; 11: 55-62.
35. Deretic V., Autophagy: an emerging immunological paradigm. J Immunol 2012; 189: 15-20.
36. Kuma A, Mizushima N, Ishihara N, et al., Formation of the approximately 350-kDa Apg12-Apg5.Apg16 multimeric complex, mediated by Apg16 oligomerization, is essential for autophagy in yeast. J Biol Chem 2002; 277: 18619-18625.
37. Fujita N, Itoh T, Omori H, et al., The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell 2008; 19: 2092-2100.
38. Rioux JD, Xavier RJ, Taylor KD, et al., Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nature Genet 2007; 39: 596-604.
39. Hampe J, Franke A, Rosenstiel P, et al., A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature Genet 2006; 39: 207-211.
40. Kuballa P, Huett A, Rioux JD, et al., Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS One 2008; 3: e3391.
41. McCarroll SA, Huett A, Kuballa P, et al., Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nature Genet 2008; 40: 1107-1112.
42. Sabers CJ, Martin MM, Brunn GJ, et al., Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270: 815-822.
43. Massey DCO, Bredin F, Parkes M,. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008; 57: 1294-1296.
44. Yin H, Li X, Zhang B, et al., Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis. Immunology 2013; 139: 494-502.
45. Duerr RH, Taylor KD, Brant SR, et al., A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.
46. Wang K, Zhang H, Kugathasan S, et al., Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn disease. Am J Hum Genet 2009; 84: 399-405.
47. Parham C, Chirica M, Timans J, et al., A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-5708.
48. Maloy KJ, Kullberg MC,. IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunol 2008; 1: 339-349.
49. Ahern PP, Schiering C, Buonocore S, et al., Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010; 33: 279-288.
50. Goodall JC, Wu C, Zhang Y, et al., Endoplasmic reticulum stress-induced transcription factor, CHOP, is crucial for dendritic cell IL-23 expression. Proc Natl Acad Sci U S A 2010; 107: 17698-17703.
51. Di Meglio P, Di Cesare A, Laggner U, et al., The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One 2011; 6: e17160.
52. + human T-cell functional responses. Proc Natl Acad Sci U S A 2011; 108: 9560-9565.
53. Pidasheva S, Trifari S, Phillips A, et al., Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. PLoS One 2011; 6: e25038.
54. Maloy KJ, Kullberg MC,. IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunol 2008; 1: 339-349.
55. Sandborn WJ, Gasink C, Gao L-L, et al., Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-1528.
56. Fitzpatrick LR,. Novel pharmacological approaches for inflammatory bowel disease: targeting key intracellular pathways and the IL-23/IL-17 axis. Int J Inflamm 2012; 2012: 389404.
57. Meylan F, Richard AC, Siegel RM,. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol Rev 2011; 244: 188-196.
58. Shih DQ, Kwan LY, Chavez V, et al., Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol 2009; 39: 3239-3250.
59. Yamazaki K, McGovern D, Ragoussis J, et al., Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005; 14: 3499-3506.
60. Kakuta Y, Kinouchi Y, Negoro K, et al., Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Gut 2006; 55: 1527-1528.
61. Shih DQ, Targan SR,. Insights into IBD pathogenesis. Curr Gastroenterol Rep 2009; 11: 473-480.
62. Takedatsu H, Michelsen KS, Wei B, et al., TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 2008; 135: 552-567.
63. Meylan F, Song YJ, Fuss I, et al., The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol 2011; 4: 172-185.
64. Taraban VY, Slebioda TJ, Willoughby JE, et al., Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol 2011; 4: 186-196.
65. Spencer SD, DiMarco F, Hooley J, et al., The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 1998; 187: 571-578.
66. Kühn R, Löhler J, Rennick D, et al., Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274.
67. Kotlarz D, Beier R, Murugan D, et al., Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012; 143: 347-355.
68. Glocker E-O, Kotlarz D, Boztug K, et al., Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-2045.
69. Glocker E-O, Frede N, Perro M, et al., Infant colitis-it's in the genes. Lancet 2010; 376: 1272.
70. Engelhardt KR, Shah N, Faizura-Yeop I, et al., Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol 2013; 131: 825-830.
71. Franke A, Balschun T, Karlsen TH, et al., Sequence variants in IL-10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nature Genet 2008; 40: 1319-1323.
72. Amre DK, Mack DR, Morgan K, et al., Interleukin 10 (IL-10) gene variants and susceptibiltiy for paediatric onset Crohn's disease. Aliment Pharmacol Ther 2009; 29: 1025-1031.
73. Noguchi E, Homma Y, Kang X, et al., A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nature Immunol 2009; 10: 471-479.
74. Moore KW, de Waal Malefyt R, Coffman RL, et al., Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
75. Chaudhry A, Samstein RM, Treuting P, et al., Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011; 34: 566-578.
76. Grütz G., New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005; 77: 3-15.
77. Braat H, Peppelenbosch MP, Hommes DW,. Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin Biol Ther 2003; 3: 725-731.
78. Martín R, Miquel S, Ulmer J, et al., Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease. Microb Cell Fact 2013; 12: 71.
79. Iliev ID, Funari VA, Taylor KD, et al., Interactions between commensal fungi and C-type lectin receptor dectin-1 influence colitis. Science 2012; 336: 1314-1317.
80. Brown GD, Gordon S,. Immune recognition: a new receptor for β-glucans. Nature 2001; 413: 36-37.
81. Ferwerda B, Ferwerda G, Plantinga TS, et al., Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361: 1760-1767.
82. Taylor PR, Tsoni SV, Willment JA, et al., Dectin-1 is required for β-glucan recognition and control of fungal infection. Nature Immunol 2006; 8: 31-38.
83. Ma J, Becker C, Lowell CA, et al., Dectin-1 triggered recruitment of light chain 3 protein to phagosomes facilitates major histocompatibility complex class II presentation of fungal-derived antigens. J Biol Chem 2012; 287: 34149-34156.
84. Eckburg PB, Bik EM, Bernstein CN, et al., Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638.
85. Ley RE, Peterson DA, Gordon JI,. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124: 837-848.
86. Lepage P, Leclerc MC, Joossens M, et al., A metagenomic insight into our gut's microbiome. Gut 2013; 62: 146-158.
87. Koenig JE, Spor A, Scalfone N, et al., Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 2011; 108 (Suppl 1): 4578-4585.
88. Matamoros S, Gras-Leguen C, Le Vacon F, et al., Development of intestinal microbiota in infants and its impact on health. Trends Microbiol 2013; 21: 167-173.
89. De La Cochetière MF, Durand T, Lepage P, et al., Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol 2005; 43: 5588-5592.
90. Dethlefsen L, Relman DA,. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011; 108 (Suppl 1): 4554-4561.
91. Frank DN, St Amand AL, Feldman RA, et al., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007; 104: 13780-13785.
92. Walker AW, Sanderson JD, Churcher C, et al., High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011; 11: 7.
93. Nagalingam NA, Lynch SV,. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012; 18: 968-984.
94. Harper PH, Lee EC, Kettlewell MG, et al., Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985; 26: 279-284.
95. Rutgeerts P, Goboes K, Peeters M, et al., Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-774.
96. Winslet MC, Allan A, Poxon V, et al., Faecal diversion for Crohn's colitis: a model to study the role of the faecal stream in the inflammatory process. Gut 1994; 35: 236-242.
97. Bennet JD, Brinkman M,. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989; 1: 164.
98. Borody TJ, Warren EF, Leis S, et al., Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37: 42-47.
99. Rietdijk ST, D'Haens GR,. Recent developments in the treatment of inflammatory bowel disease. J Digest Dis 2013; 14: 282-287.
100. Prantera C, Lochs H, Grimaldi M, et al., Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-481.
101. Gionchetti P, Rizzello F, Ferrieri A, et al., Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44: 1220-1221.
102. Saleh M, Elson CO,. Experimental inflammatory bowel disease: insights into the host-microbiota dialog. Immunity 2011; 34: 293-302.
103. Nell S, Suerbaum S, Josenhans C,. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nature Rev Microbiol 2010; 8: 564-577.
104. Gordon S., Pattern recognition receptors: doubling up for the innate immune response. Cell 2002; 111: 927-930.
105. Kalinski P, Hilkens CMU, Wierenga EA, et al., T-cell priming by type-1and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999; 20: 561-567.
106. de Jong EC, Vieira PL, Kalinski P, et al., Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J Immunol 2002; 168: 1704-1709.
107. Dolganiuc A, Kodys K, Kopasz A, et al., Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 2003; 170: 5615-5624.
108. Smits HH, Engering A, van der Kleij D, et al., Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 2005; 115: 1260-1267.
109. Uematsu S, Fujimoto K, Jang MH, et al., Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nature Immunol 2008; 9: 769-776.
110. + dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013; 38: 970-983.
111. Steinman RM, Hawiger D, Nussenzweig MC,. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
112. Reid G, Younes JA, Van der Mei HC, et al., Microbiota restoration: natural and supplemented recovery of human microbial communities. Nature Rev Microbiol 2011; 9: 27-38.
113. Naidoo K, Gordon M, Fagbemi AO, et al., Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011; 12: CD007443.
114. Butterworth AD, Thomas AG, Akonbeng AK,. Probiotics for remission in Crohn's disease. Cochrane Database Syst Rev 2008; 3.
115. De Greef E, Vandenplas Y, Hauser B, et al., Probiotics and IBD. Acta Gastroenterol Belg 2013; 76: 15-19.
116. Klaenhammer TR, Kleerebezem M, Kopp MV, et al., The impact of probiotics and prebiotics on the immune system. Nature Rev Immunol 2012; 12: 728-734.
117. Braat H, Rottiers P, Hommes DW, et al., A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 754-759.
118. Iwasaki A., Mucosal dendritic cells. Annu Rev Immunol 2007; 25: 381-418.
119. Bogunovic M, Ginhoux F, Helft J, et al., Origin of the lamina propria dendritic cell network. Immunity 2009; 31: 513-525.
120. Varol C, Vallon-Eberhard A, Elinav E, et al., Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 2009; 31: 502-512.
121. + dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 2005; 202: 1063-1073.
122. + dendritic cells: master regulators of tolerance? Trends Immunol 2011; 32: 412-419.
123. Agace WW, Persson EK,. How vitamin A metabolizing dendritic cells are generated in the gut mucosa. Trends Immunol 2012; 33: 42-48.
124. + conventional dendritic cells. J Exp Med 2010; 207: 823-836.
125. + dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation. Immunity 2013; 38: 581-595.
126. + lamina propria dendritic cells instruct intestinal epithelial cells to express antimicrobial proteins in response to Toll-like receptor 5 activation. Immunity 2012; 36: 276-287.
127. + dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity 2013; 38: 322-335.
128. + dendritic cells regulates intestinal homeostasis by promoting IL-10 production. J Immunol 2012; 188: 4736-4740.
129. Mann ER, Landy JD, Bernardo D, et al,. Intestinal dendritic cells: their role in intestinal inflammation, manipulation by gut microbiota and differences between mice and men. Immunol Lett 1938; 150: 30-40.
130. Bell SJ, Rigby R, English N, et al., Migration and maturation of human colonic dendritic cells. J Immunol 2001; 166: 4958-4967.
131. Silva MA,. Intestinal dendritic cells and epithelial barrier dysfunction in Crohn's disease. Inflamm Bowel Dis 2009; 15: 436-453.
132. Varol C, Zigmond E, Jung S,. Securing the immune tightrope: mononuclear phagocytes in the intestinal lamina propria. Nature Rev Immunol 2010; 10: 415-426.
133. - dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur J Immunol 2003; 33: 143-151.
134. Hart AL, Al-Hassia HO, Rigby RJ, et al., Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005; 129: 50-65.
135. Takenaka S, Safroneeva E, Xing Z, et al., Dendritic cells derived from murine colonic mucosa have unique functional and phenotypic characteristics. J Immunol 2007; 178: 7984-7993.